L-Tryptophan for Depression

Verdict: Weak, dated evidence; not a proven depression treatment

L-tryptophan supplements have only weak, outdated support for treating depression, and they are not an established therapy. The small positive signal comes from a handful of old, low-quality trials, while regulators and clinics stop short of endorsing it for mood.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a Weak (C) grade because the entire human evidence base is small and aged. The Shaw systematic review and meta-analysis (PMID 11687048, PMID 12169147) located 108 trials but found only 2 (64 patients total) of acceptable quality. Those pooled to a Peto odds ratio of 4.1, yet the confidence interval was very wide (95% CI 1.3-13.2) and the authors themselves judged the evidence insufficient due to tiny samples and likely publication bias.

Supporting data are thin and indirect. The only randomized trial here added tryptophan to fluoxetine in just 30 people and reported no p-values (PMID 11022398). A depletion review (PMID 11331552) shows that lowering tryptophan can worsen mood in already-treated patients, supporting a serotonergic mechanism, but it is not a treatment trial. No modern, high-quality RCTs exist; the evidence has essentially not been updated in over two decades.

Authorities reinforce the caution. The US FDA lists L-tryptophan only as a nutrient supplement, with a notable safety history (the 1989 eosinophilia-myalgia syndrome outbreak), and EFSA rejected mood-enhancement health claims for lack of a cause-and-effect relationship. The Cleveland Clinic notes only that low serotonin is associated with depression, without endorsing tryptophan as a treatment. There is also a real serotonin-syndrome risk when combined with antidepressants.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.52
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
79%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.522
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Tryptophan and 5-hydroxytryptophan for depression
PMID: 11687048 2001 系統性回顧 n = 64
Finding: 108 trials located; only 2 (64 patients) met quality criteria; combined Peto OR 4.10 (95% CI 1.28-13.15) favouring active over placebo, but evidence judged insufficient.
Effect size: Peto OR 4.10 (95% CI 1.28-13.15)
View on PubMed
Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis
PMID: 12169147 2002 統合分析 n = 64
Finding: Same 2 qualifying studies; Peto OR 4.1 (95% CI 1.3-13.2) better than placebo, but authors conclude insufficiently evaluated due to small sample and publication bias.
Effect size: Peto OR 4.1 (95% CI 1.3-13.2)
View on PubMed
Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine for MDD
PMID: 11022398 2000 RCT (double-blind) n = 30
Finding: Tryptophan+fluoxetine showed significantly greater depression score reduction at week 1 vs placebo+fluoxetine, plus protective slow-wave sleep effect; no p-values reported.
🟠 Limited quality Academic
View on PubMed
Tryptophan depletion and its implications for psychiatry
PMID: 11331552 2001 系統性回顧
Finding: Depletion causes mild mood lowering in healthy volunteers and relapse in remitted/treated depressed patients, but no worsening in untreated depressed subjects; supports serotonergic role.
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
L-Tryptophan — CAS Reg. No. 73-22-3; 21 CFR 172.320; Permitted Technical Effect: NUTRIENT SUPPLEMENT. Listed in FDA 'Substances Added to Food' inventory (formerly EAFUS); also recognized as L-tryptophane and alpha-amino-3-indolepropionic acid. source↗
L4d TW TFDA / 衛福部
Neutral
通過審查的產品會給予健康食品(小綠人)標章,第一軌的產品上標有「衛部健食字第A00000號」,第二軌的產品標有「衛部健食規字第000000號」。 source↗
L5c Cleveland Clinic
Neutral
Low levels of serotonin are associated with depression. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-depression-INT-tryptophan-001 繁體中文版 →